The field of 3D bioprinting has emerged as a remarkable technological advancement in recent years. This revolutionary technique involves the fabrication of living tissues, including blood vessels, bones, hearts, and skin, through the process of additive manufacturing, commonly known as 3D printing. Unlike traditional printing, bioprinting not only requires living cells but also relies on a conducive environment to sustain their vitality, encompassing essential elements such as nourishment, hydration, and oxygenation. To facilitate optimal cell growth, researchers employ the strategic placement of cells around 3D scaffolds made from biodegradable polymers or collagen, providing a framework for the cells to mature into fully functional tissues.
The transformative potential of bioprinting in the healthcare sector cannot be overstated. With a staggering 21 patients succumbing to organ transplant shortages every day, as reported by the World Health Organization (WHO), the urgency to find innovative solutions has never been more critical. Bioprinted organs offer a promising avenue to address this pressing issue by circumventing the complexities of donor-patient matching and eliminating the long waiting lists for organ transplantation, ultimately saving countless lives and revolutionizing the field of healthcare.
Driven by these groundbreaking possibilities, the market for bioprinting is experiencing exponential growth. In 2021, BCC Research estimated the global bioprinting market's value at $2.1 billion, and projections indicate a robust compound annual growth rate (CAGR) of 16.2%. By 2027, it is anticipated that the market will reach a staggering $5 billion, reflecting the tremendous commercial potential in this rapidly advancing field.
As we delve into the realm of bioprinting, we will explore five companies developing this cutting-edge technology, each contributing their unique expertise and innovations to shape the future of 3D bioprinting.
Founded in 2016 and headquartered in Gothenburg, Cellink has rapidly established itself as a global leader in 3D bioprinting, offering high-tech bioprinting equipment and driving advancements in cell printing and research collaborations. Recognizing the need for global growth, Cellink sought to expand into the APAC region in 2017, and they turned to Business Sweden for support in developing a partnership strategy and establishing connections with key players in Japan and Korea.
Over the past 5 years their product portfolio has expanded significantly, with the addition of approximately 10 different instruments and over 60 bioinks, contributing to their position as a leader in 3D bioprinting.Their products are utilized in more than 1,800 laboratories across 65 countries and are trusted by the world's top 20 pharmaceutical companies.
Continue reading
This content available exclusively for BPT Mebmers
We use cookies to personalise content and to analyse our traffic.
You consent to our cookies if you continue to use our website. Read more details in our
cookies policy.
